# Regeneron Major US biotech (Eylea, Dupixent; the COVID antibody cocktail Trump received in October 2020). In the vault's frame it appears twice in 2025–26: as the initial $256M winning bidder for bankrupt [[23andMe]] (it declined to raise when the auction reopened, losing to Wojcicki's TTAM), and as a signer of a Trump most-favored-nation drug-pricing deal in April 2026 — one of 17 manufacturers covering ~86% of the branded market. > Status: stub — expand with the MFN deal terms, the Trump COVID treatment episode, and founders Schleifer/Yancopoulos. ## See Also - [[Biotech Sector]] - [[Big Pharma]] - [[23andMe]]